{"id":"fosfomycin-and-imipenem","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Seizures (imipenem-related)"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosfomycin inhibits MurA enzyme in peptidoglycan synthesis, while imipenem is a broad-spectrum beta-lactam that inhibits penicillin-binding proteins. This combination provides synergistic coverage against multidrug-resistant gram-negative and gram-positive bacteria, including some carbapenem-resistant organisms. The dual mechanism reduces the likelihood of resistance development.","oneSentence":"Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:46:52.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections caused by multidrug-resistant gram-negative organisms"},{"name":"Hospital-acquired and ventilator-associated pneumonia"},{"name":"Complicated urinary tract infections"}]},"trialDetails":[{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00871104","phase":"PHASE4","title":"Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-07","conditions":"Infective Endocarditis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fosfomycin and imipenem","genericName":"Fosfomycin and imipenem","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections. Used for Serious bacterial infections caused by multidrug-resistant gram-negative organisms, Hospital-acquired and ventilator-associated pneumonia, Complicated urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}